Document:

EX-10.1

 Exhibit 10.1 
  

 
 Heather Cohen 
 EVP Human
Resources 
 11311 Concept Blvd 
 Largo, FL 33773 

December 6, 2022 
 Daniel S. Jonas, Esq. 

1901 Walnut Street, Apartment 12B 
 Rittenhouse Plaza 

Philadelphia, PA 19103 
  

	 	Re:	     Employment Transition and Retirement Agreement 

Dear Dan, 
 This letter confirms our recent
discussions regarding your continued at-will employment with CONMED Corporation (the “Company”), including your planned transition and retirement from your current position and duties with the
Company. On behalf of the Board of Directors of the Company (the “Board”), I want to thank you for your years of leadership and your willingness to provide continued service as set forth herein. 

 

	1)	 Continued Service: 

 

	 	a)	 Beginning on December 6, 2022 (the “Transition Date”), you will transition to Special
Counsel & Corporate Secretary and will continue in such position through December 31, 2024. Your cash compensation during this period will be as follows: (i) at your current compensation level (base salary and target bonus) from
the Transition Date through December 31, 2022; then (ii) $400,000 annual base salary (eligible for an annual base salary adjustment at the sole discretion of the Company at the same time as other employees receive annual adjustments) and a 40%
target bonus from January 1, 2023 through December 31, 2024. 

  

	 	b)	 Beginning on January 1, 2025, you will transition to Corporate Secretary and will continue in such
position through July 1, 2026. Your cash compensation during this time will be equal to $896,295, paid in equal, regular payroll installments through this period and subject to applicable taxes and withholding. 

 

	 	c)	 As a member of the senior management team, you will remain eligible to receive equity. 

  
 Page 1 | 12 

 

 
  

	 	d)	 You will also remain eligible to participate in and receive benefits under the Company’s welfare benefit
plans (e.g., medical, dental, and vision) provided you continue to satisfy the applicable eligibility requirements for such benefits during this period. You will also remain eligible to participate in and receive benefits under the Company’s
Benefits Restoration Plan and the Company’s Retirement Savings Plan. 

  

	 	e)	 Upon presentation of reasonable substantiation and documentation as required by the Company, and subject to the
Company’s applicable travel and entertainment policies as may be in effect from time to time, you shall continue to be reimbursed for all reasonable out-of-pocket
business expenses incurred and paid by you and in connection with the performance of your duties hereunder. 

  

	2)	 Separation Date: Your service as an employee will end on July 1, 2026 unless
terminated earlier by you or the Company hereunder (such termination date, the “Separation Date”). Following the Separation Date, your employment with the Company will cease. 

 

	3)	 Releases: In connection with the execution of this Letter Agreement, you agree to
execute the release attached hereto as Annex A (the “Release”) within 30 days after the date of this letter agreement. You also agree to execute a supplemental release in a form substantially identical to the Release (the
“Supplemental Release”) within 30 days after the Separation Date but in no event earlier than the Separation Date. 

  

	4)	 Duties: Effective as of the Transition Date, your duties will include supporting
and providing guidance to the Company and such other reasonable duties as may be assigned to you by the Chief Executive Officer or myself. During this time, you will continue to provide services as a full-time employee of the Company and will devote
the appropriate business time and attention required to fulfill your service. 

  

	5)	 Equity Awards: You shall remain eligible to receive equity awards and, subject to
applicable service requirements and compliance with the release requirements set forth above, your equity awards shall continue to vest through July 1, 2026 according to their terms (which are unchanged). All equity awards shall remain subject
to the terms of the applicable award agreements and the Company’s Amended and Restated 2018 Long-Term Incentive Plan (the “LTIP”), as applicable. 

 

	6)	 Severance Entitlements: You waive any claim to receive payments or other benefits
under the Company’s Executive Management Severance Plan (“Severance Plan”) or the CONMED Severance Plan. 

  

	 	a)	 Upon a termination of your employment as a result of your death or disability, or by the Company for any reason
other than your gross misconduct, before January 1, 2025, the Company will, subject to your (or your estate or beneficiary’s) execution and non-revocation of the Supplemental Release (defined below)
within 30 days following the Separation Date, pay you $600,000. This amount will be paid to you in a single lump sum within 30 days of such Supplemental Release becoming effective, subject to the provisions of “Section 409A” set forth
below. 

  
 Page 2 | 12 

 

 
  

	 	b)	 Upon a termination of your employment as a result of your death or disability or by the Company for any reason
on or after January 1, 2025 and prior to July 1, 2026, the Company will, subject to your (or your estate or beneficiary’s) execution and non-revocation of the Supplemental Release within 30 days
following the Separation Date, pay you any sums not already paid to you under Section 1(b) above. This amount will be paid to you in a single lump sum within 30 days of such Supplemental Release becoming effective, subject to the provisions of
“Section 409A” set forth below. 

  

	7)	 COBRA Eligibility: Following the Separation Date, you will be entitled to continued
health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”), if applicable, for a period in accordance with the requirements under COBRA. Except as otherwise provided in the Severance Plan in
respect of a “Qualifying Termination” that occurs prior to January 1, 2025, you will be solely responsible for paying the full cost of the premiums for such COBRA coverage, and such coverage shall not be provided if during such period
you are or become ineligible under the provisions of COBRA for continuing coverage. 

  

	8)	 Restrictive Covenants: In connection with your transition, you agree to be bound by
the covenants and provisions in Annex B, which apply during your employment with the Company and after your employment with the Company terminates for any reason. You acknowledge the potential restrictions on your future employment imposed by
such covenants and provisions are reasonable in both duration and geographic scope and in all other respects. 

  

	9)	 Withholding Taxes: The Company shall withhold from all payments due to you (or your
beneficiary or estate) hereunder all taxes which, by applicable federal, state, local or other law, the Company is required to withhold therefrom. 

  

	10)	 Section 409A: The payments under this letter are
not intended to constitute “‘deferred compensation” subject to Section 409A of the Internal Revenue Code (“‘Section 409A”’). The parties agree to interpret and administer this letter in a manner intended to
comply with Section 409A as applicable. If and to the extent that any payment under this letter is determined by the Company to constitute “non-qualified deferred compensation” subject to
Section 409A (because a payment is not a “short-term deferral” and not an involuntary severance payment under Treas. Reg. §1.409A-l(b)(9)(iii)) and that is payable to you by reason of your
termination of employment, then (1) such payment or benefit shall be made or provided to you only upon a “separation from service” as defined for purposes of Section 409A under applicable regulations and (2) if you are a
“specified employee” (within the meaning of Section 409A and as determined by the Company), such payment will not be made or provided before the date that is six months after the date of your separation from service (or your earlier
death or a change in ownership or effective control within the meaning of Section 409A). To the extent applicable, each payment under this letter shall be treated as a separate payment for the purposes of Section 409A.

  
 Page 3 | 12 

 

 
  

	11)	 Choice of Law and Forum Selection: This Agreement, and all claims or causes of action
(whether in contract or tort) that may be based upon, arise out of or relate to the execution or performance hereof, shall be governed by the internal Laws of the State of Delaware, without giving effect to any choice of Law or conflict of Laws
rules or provisions (whether of the State of Delaware or any other jurisdiction) that would cause the application of the Laws of any jurisdiction other than the State of Delaware. Any suit, action or other proceeding arising out of or relating to
this Agreement or any transaction contemplated hereby shall be brought exclusively in the Delaware Court of Chancery in New Castle County, or in the event (but only in the event) that such court does not have subject matter jurisdiction over such
action, the United States District Court for the District of Delaware, and each of the parties hereto hereby irrevocably submits to the exclusive jurisdiction of such courts for the purpose of any such suit, action or other proceeding. A final
judgment in any such suit, action or other proceeding may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law. Each Party irrevocably and unconditionally waives any objection to the laying of venue of
any action, suit or proceeding arising out of this Agreement or the transactions contemplated hereby in such courts, and hereby irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such action, suit or
proceeding brought in any such court has been brought in an inconvenient forum. Each Party further agrees that service of any process, summons, notice or document by U.S. registered mail to such Party’s respective address set forth herein shall
be effective service of process for any such action, suit or proceeding. 

 Thank you again for your service. 

 

			
	CONMED Corporation
	
	 /s/ Heather L. Cohen

	By:	 	Heather L. Cohen
	Title:	 	EVP – Human Resources

  

	
	ACCEPTED AND AGREED:
	
	 /s/ Daniel S. Jonas

	Daniel S. Jonas

  
 Page 4 | 12 

 

 
  

 ANNEX A 

This Agreement (the “Agreement”) is entered into by and between CONMED Corporation (the “Company”) and Daniel S. Jonas
(“Employee” or “You”) in full and complete settlement of all issues concerning Employee’s employment through the Effective Date (as defined herein). As used in this Agreement, the term “Company” shall include
CONMED Corporation, its affiliates, subsidiaries (including Linvatec Corporation), successors and assigns, all of its current and former officers, directors, employees, and agents (in their individual and representative capacities). 

WHEREAS, Employee acknowledges that he is knowingly and voluntarily entering into this Agreement and that by signing this Agreement he is
receiving payment and/or other consideration from the Company to which he was not or would not otherwise be entitled. 
 NOW, THEREFORE, in
consideration of the above premises and of the mutual agreement and undertakings hereinafter set forth in the Letter Agreement dated [date] (the “Letter Agreement”), the Company and Employee further agree as follows: 

 

	 	1)	 Last Day of Employment. July 1, 2026, unless earlier terminated by the Company or Employee.

  

	 	2)	 Company Property. Employee acknowledges that, effective as of the last day of
employment, he has returned (or will return) all of the Company’s property, whether created by Employee or others, including but not limited to, any keys, credit cards, computers, computer disks, zip or flash drives, documents, identification
cards or badges, access codes or devices, phones, smartphones, hand-held electronic devices, electronic storage devices, software, electronically stored documents or files, physical files, disks, data, manuals, reports, letters, memoranda,
agreements, and any other Company property in Employee’s possession, custody, or control. 

  

	 	3)	 Letter Agreement Benefits. In consideration for Employee’s execution of the Letter Agreement
and the general releases contained herein, and without any other obligation to do so, the Company will provide Employee with the payments contemplated by the Letter Agreement, less applicable federal, state, local, and other legally required payroll
deductions in accordance with the Company’s standard payroll practices (the “Letter Agreement Benefits”). Employee understands, acknowledges, and agrees that if he did not execute this Agreement, he would receive less and different
benefits. 

  

	 	4)	 General Release of Claims. In consideration for the Letter Agreement Benefits, Employee, on
behalf of himself, his descendants, dependents, heirs, executors, administrators, assigns, and successors, Employee voluntarily, knowingly and willingly waives and releases, and promises never to assert, any and all claims that Employee has or might
have against the Company, and/or its predecessors, successors, past, current and future parents, subsidiaries, related entities, officers, directors, shareholders, agents, partners, employees, successors or assigns (collectively, the
“Releasees”), relating to any 

 

 
  

	 	
aspect of Employee’s employment, employment compensation, resignation or termination of employment, including any and all rights or claims of unlawful retaliation, discrimination or
harassment on the basis of age, race, sex, marital status, disability, national origin, religion, or any other basis under federal, state, or local law. Those claims being released and discharged include, but are not limited to: claims arising under
any other federal, state or local fair employment statute, code or ordinance, contract law; torts of all kinds including, but not limited to, negligence claims and fraudulent inducement to enter into this contract, misrepresentation, negligent or
otherwise, fraud, defamation, slander, libel, duress, fraudulent inducement, workers’ compensation retaliation, interference with an advantageous business relationship, negligent employment, including negligent hiring, negligent retention and
negligent supervision; claims of breach of contract, whether actual or implied, written or oral; promissory estoppel, quantum meruit or the like, and any and all claims for attorneys’ fees, any federal, state and local statutory
or common law; claims for personal, bodily or emotional injury and monetary loss, without limitation, relating to any workers’ compensations laws, tort, contract (express or implied), or any other common law theory; all claims for retaliation
or discrimination of any type; and all claims for employment-related benefits of any type and any and all rights or claims to attorneys’ fees; claims of any violation of any pension or welfare plans or any other benefit plan or arrangement,
including, without limitation, any claims under the Employee Retirement Income Security Act of 1974 (“ERISA”) [29 U.S.C. Sections 1001-1461], as amended, including claims for breach of fiduciary duty under ERISA; claims under the Fair
Housing Act [42 U.S.C. Section 3604 et. seq.], as amended; Title IX of the Education Amendments of 1972 [20 U.S.C. Sections 1681 et. seq.], as amended; the Federal False Claims Act [18 U.S.C. Sections 287, et seq.], as amended
(“FFCA”); the Program Fraud Civil Remedies Act [38 C.F.R. 42.1, et seq.], as amended (“PFCRA”); the Fair Credit Reporting Act, as amended (“FCRA”); the Uniformed Services Employment and Reemployment Rights Act of 1994
[38 U.S.C. Sections 4301-4333], as amended (“USERRA”); the National Labor Relations Act [29 U.S.C. Sections 151-169], as amended (“NLRA”); the Worker Adjustment and Retraining
Notification Act [29 U.S.C. Sections 2101 et seq.], as amended (“WARN”); the Occupational Safety and Health Act [29 U.S.C. Sections 651-678], as amended (“OSHA”); the Fair Labor Standards
Act [29 U.S.C. Sections 201-219], as amended (“FLSA”); claims or rights under state and federal whistleblower legislation including the Consolidated Omnibus Budget Reconciliation Act of 1985
[Pub. L. 99- 509], as amended (“COBRA”); the Sarbanes-Oxley Act of 2002 15 U.S.C. § 7201, et seq.; (“S-OA”); the Health Insurance
Portability and Accountability Act of 1996, as amended (“HIPAA”); the Family and Medical Leave Act [29 U.S.C. Sections 2601-2654], as amended (“FMLA”); ·the Congressional Accountability Act of 1995 [2 U.S.C.
Sections 1311-1317], as amended; the Age Discrimination in Employment Act [29 U.S.C. § 621 et seq.] (“ADEA”), as amended; the Americans with Disabilities Act [42 U.S.C. Sections 12101-12213], as amended (“ADA”); the ADA
Amendments Act of 2008 (“ADAAA”); the Rehabilitation Act of 1973 [29 U.S.C. Section 791, et.seq.], as amended; the Employee Polygraph Protection Act of 1988 [29 U.S.C. Sections 2001, et. seq.], as amended
(“PPA”); the Internal Revenue Code [Title 26, U.S.C.], as amended (“IRC”); the Equal Pay Act [29 U.S.C. Section 206(d)], as amended (“EPA”); the Lilly Ledbetter Fair Pay Act of 2009; Title VII of the Civil Rights
Act of 1964 [42 U.S.C. Sections 2000e- 2000e-17J, 

 

 
  

	 	
as amended (“CRA”); the Civil Rights Act of 1991; Elliott-Larsen Civil Rights Act, as amended; the Revised Statutes [42 U.S.C. Sections 1981, 1983 or 1985], as amended; claims
under the Florida Civil Human Rights Act [Fla. Stat. Ann. Sections760.01 et seq.], as amended; The AIDS Act [Fla. Stat. Ann. Sections 760.50 et seq.); Florida Wage Discrimination Law [Fla. Stat. Ann. Section 725.07), as amended; Florida False
Claims Act [Fla. Stat. Ann. Sections 68.081 et seq.]; the Florida Minimum Wage Act; Whistleblower’s Act [Fla. Stat. Ann. Sections 112.3187 et seq.]; Wage Payment Laws [Fla. Stat. Ann. Sections 448.109 to 448.110]; worker’s compensation
retaliation; claims under the New York Labor Law, New York State Human Rights Law [N.Y. Exec. Law§§ 296, et. seq.]; New York City Commission on Human Rights Law [NYC Code§ 8-101]; New
York Equal Pay Law [N.Y. Lab. Law§ 194]; New York Equal Rights Law (N.Y. Civ. Rights Law§ 40]; New York Off-duty Conduct Lawful Activities Discrimination Law [N.Y. Lab. Law.§ 201-d]; New York Minimum Wage Act [N.Y. Lab. Law§§ 650 to 665]; New York Wage and Hour Law [N.Y. Lab. Law §§ 190, et seq.]; New York Whistleblower Statute [N.Y. Lab. Law § 740]; New York
Workers’ Adjustment and Retraining Notification Acts, as amended (the New York “Warn” Laws)[N.Y. Lab. Art. 25-A, §§ 860A to 8601]; claims for severance payments or other benefits
pursuant to the CONMED Executive Management Severance Plan and the CONMED Severance Plan. Employee specifically acknowledges and agrees that he is waiving on behalf of himself and his attorneys all claims for fees and expenses and court costs.
Employee is also waiving his right to recover in his own lawsuit, as well as the right to recover in a suit brought by any other entity or person on Employee’s behalf. Employee is not waiving any rights or claims which may arise after the date
Employee signs this agreement. 

 This Agreement does not prohibit Employee from challenging the validity of this
Agreement’s waiver and release of claims under the ADEA. Also excluded from the General Release is Employee’s right to file a charge with an administrative agency or participate in any agency investigation. Employee is, however, waiving
his right to recover money in connection with such a charge or investigation. Employee is also waiving his right to recover money in connection with a charge filed by any other individual or by the Equal Employment Opportunity Commission or any
other federal state or local agency provided that Employee does not waive, and this letter shall not be read as requiring Employee to waive, any right Employee may have to receive an award for information provided to any governmental entity. 

 

	 	5)	 Breach of Agreement by Employee. In the event that Employee materially breaches any of his
obligations under this Agreement or as otherwise imposed by law, the Company will be entitled to recover all of the benefits paid under the Letter Agreement and to obtain all other relief provided in law or equity. 

 

	 	6)	 Savings Clause. The provisions of this Agreement are severable, and if any part of it is found to
be unenforceable, the other provisions nonetheless shall remain fully valid and enforceable. 

  

	 	7)	 Entire Agreement. This Agreement sets forth the entire agreement between Employee and the
Company, other than any contemporaneous agreement, any employment 

 

 
  

	 	
agreement signed by Employee at the time of hire, the Letter Agreement,1 and any supplemental release required thereunder and fully supersedes
any and all prior agreements or understandings between the parties hereto pertaining to the subject matter of this Agreement other than the Letter Agreement. By countersigning this Agreement Employee acknowledges that in doing so he have not relied
upon any representation or statement not set forth in this Agreement made by the undersigned or any other representative of the Company, with regard to the subject matter, basis or effect of this Agreement or otherwise, other than in the Letter
Agreement. 

  

	 	8)	 Choice of Law and Forum Selection. This Agreement, and all claims or causes of action (whether in
contract or tort) that may be based upon, arise out of or relate to the execution or performance hereof, shall be governed by the internal Laws of the State of Delaware, without giving effect to any choice of Law or conflict of Laws rules or
provisions (whether of the State of Delaware or any other jurisdiction) that would cause the application of the Laws of any jurisdiction other than the State of Delaware. Any suit, action or other proceeding arising out of or relating to this
Agreement or any transaction contemplated hereby shall be brought exclusively in the Delaware Court of Chancery in New Castle County, or in the event (but only in the event) that such court does not have subject matter jurisdiction over such action,
the United States District Court for the District of Delaware, and each of the parties hereto hereby irrevocably submits to the exclusive jurisdiction of such courts for the purpose of any such suit, action or other proceeding. A final judgment in
any such suit, action or other proceeding may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law. Each Party irrevocably and unconditionally waives any objection to the laying of venue of any action,
suit or proceeding arising out of this Agreement or the transactions contemplated hereby in such courts, and hereby irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such action, suit or proceeding
brought in any such court has been brought in an inconvenient forum. Each Party further agrees that service of any process, summons, notice or document by U.S. registered mail to such Party’s respective address set forth herein shall be
effective service of process for any such action, suit or proceeding. 

  

	 	9)	 Age Discrimination Release Notification. You acknowledge that as part of this Agreement You are
releasing and waiving all charges, claims, and complaints under the Age Discrimination in Employment Act (“ADEA”) and you are agreeing not to sue the Releasees in connection with any of Your rights under the ADEA. In order for you to waive
Your ADEA rights through this Agreement, pursuant to the requirements of 29 U.S.C. 1626, You acknowledge and agree that: 

  

	 	a)	 You knowingly and voluntarily execute this Agreement and release, waive, and agree not to sue the Releasees;
and 

  

	 	b)	 the release, waiver and agreement not to sue includes settlement of any allegation of age discrimination
arising under the ADEA; and 

  

	 	c)	 the release, waiver, and agreement not to sue includes all claims under the ADEA arising up to and including
the date of execution of this release, but not claims occurring thereafter; and 

 

 
  

	 	d)	 You have been advised to consult with an attorney concerning Your rights and obligations under the release,
waiver, and agreement not to sue and before signing this Agreement; and 

  

	 	e)	 this Agreement is written in a manner that You can understand, and You have fully considered the terms and
conditions of this Agreement; and 

  

	 	f)	 You are not releasing or waiving any rights that You are prohibited by law, rule, or regulation from releasing
or waiving; and 

  

	 	g)	 You have been given a reasonable period of time from receipt of this Agreement, to consider this Agreement
before executing it and that you may accept and sign this Agreement before expiration of the twenty-one (21) daytime period following your receipt of this Agreement, but you are not required to do so by
the Company; and 

  

	 	h)	 You understand that after signing this Agreement, you may revoke your acceptance within seven (7) days by
providing written notice of revocation to the EVP of HR at 11311 Concept Blvd, Largo, FL 33773. This Agreement will become effective on the eighth (8th) day following your signature (the “Effective Date”). 

[Signature page follows] 

 

 
  

 TO THE EMPLOYEE: THIS IS AN IMPORTANT DOCUMENT. WHEN YOU SIGN THIS AGREEMENT, YOU ARE WAIVING CERTAIN RIGHTS
THAT YOU HAVE UNDER STATE AND FEDERAL EMPLOYMENT LAWS. YOU MAY DESIRE TO CONSULT WITH A LAWYER BEFORE SIGNING THIS DOCUMENT. 
 IN WITNESS WHEREOF, the
parties have executed this Agreement. 
  

			
	CONMED Corporation
	
	  

	By:	 	Heather L. Cohen
	Executive Vice President – HR

  

	
	ACCEPTED AND AGREED:
	
	  

	Daniel S. Jonas

 

 
  

 Annex B 

To protect the confidential information and other trade secrets of the Company, you agree that: 

1) Covenant not to Solicit: During your employment with the Company and for a period of 12 months thereafter, you will not: (i) Solicit any Client
to transact business with a Competitive Enterprise or to reduce or refrain from doing any business with the Company, (ii) interfere with or damage any relationship between the Company and a Client or (iii) Solicit anyone who is then an
employee of the Company to resign from the Company or to apply for or accept employment with any other business or enterprise except pursuant to a general solicitation of employment which is not directed specifically to any such employees. 

2) Covenant not to Compete: During your employment with the Company and for a period of 12 months thereafter, you will not, directly or indirectly,
alone or jointly, with any person or entity, participate in, engage in, consult with, advise, be employed by, own (wholly or partially), possess an interest in, or in any other manner be involved with, any Competitive Enterprise. Notwithstanding the
foregoing, you will not be prohibited from passively owning less than 1% of the securities of any publicly traded corporation. You agree that the covenants contained in this bullet are reasonable and desirable to protect the Confidential Information
of the Company and its affiliates. 
 3) Covenant not to Disparage: During your employment with the Company and thereafter, you will not make
any statement that would libel, slander or disparage the Company, any of its subsidiaries or their respective past or present officers, directors, employees or agents; and the Company will not, and will instruct its senior executives and board
members not to, make any statement that would libel, slander or disparage you. Nothing herein shall prevent you from responding accurately and fully to any question, inquiry or request for information when required by legal process; provided,
however, that you will provide the Company with reasonable prior written notice before responding to such a question, inquiry or request, unless such notice to the Company is prohibited under applicable law. Notwithstanding anything to the contrary
in this letter or otherwise, nothing shall limit your rights under applicable law to provide truthful information to any governmental entity or to file a charge with or participate in an investigation conducted by any governmental entity.
Notwithstanding the foregoing, you agree to waive your right to recover monetary damages in connection with any charge, complaint or lawsuit filed by you or anyone else on your behalf (whether involving a governmental entity or not); provided that
you do not waive, and this letter shall not be read as requiring you to waive, any right you may have to receive an award for information provided to any governmental entity. 

4) Confidentiality: During your employment and thereafter, you will hold in a fiduciary capacity for the benefit of the Company all trade
secrets and confidential information, knowledge or data relating to the Company and its businesses and investments, which will have been obtained by you during your employment by the Company and which is not generally available public knowledge.
Except as may be required or appropriate in connection with your carrying out your duties you will not, without the prior written consent of the Company or as may otherwise be required by law or any legal process, any statutory obligation or order
of any 

 

 
  

 
court or statutory tribunal of competent jurisdiction, or as is necessary in connection with any adversarial proceeding against the Company (in which case you will use your reasonable best
efforts in cooperating with the Company in obtaining a protective order against disclosure by a court of competent jurisdiction), communicate or divulge any such trade secrets, information, knowledge or data to anyone other than the Company and
those designated by the Company or on behalf of the Company in the furtherance of its business or to perform duties hereunder. 
 You are hereby notified
that the immunity provisions in Section 1833 of title 18 of the United States Code provide that an individual cannot be held criminally or civilly liable under any federal or state trade secret law for any disclosure of a trade secret that is
made (1) in confidence to federal, state or local government officials, either directly or indirectly, or to an attorney, and is solely for the purpose of reporting or investigating a suspected violation of the law, (2) under seal in a
complaint or other document filed in a lawsuit or other proceeding, or (3) to your attorney in connection with a lawsuit for retaliation for reporting a suspected violation of law (and the trade secret may be used in the court proceedings for
such lawsuit) as long as any document containing the trade secret is filed under seal and the trade secret is not disclosed except pursuant to court order. 

The following terms used in this Annex B have the meanings indicated below: 
  

	•	 	 “Client’ means any client or prospective client of the Company to whom you provided services, or
for whom you transacted business, or whose identity became known to you in connection with your relationship with or employment by the Company. 

  

	•	 	 “Competitive Enterprise” means (i) any business competing with the businesses of the
Company or any of its subsidiaries, or (ii) any business in which the Company or any of its subsidiaries has entertained discussions or has requested and received information relating to the acquisition of such business by the Company or any of
its subsidiaries during the six-month period immediately preceding the date of your termination of employment. 

  

	•	 	 “Solicit’ means any direct or indirect communication of any kind, regardless of who initiates
it, that in any way invites, advises, encourages or requests any person to take or refrain from taking any action. 

 It is the intent and
desire of the parties that the restrictive provisions of this Annex B be enforced to the fullest extent permissible under the laws and public policies as applied in each jurisdiction in which enforcement is sought. If any particular provision
of this Annex B is determined to be invalid or unenforceable, such covenant shall be amended, without any action on the part of either party, to delete the portion determined to be invalid or unenforceable (such deletion to apply only with
respect to the operation of such covenant in the particular jurisdiction in which such adjudication is made). Your obligations under this Annex B shall survive the termination of your employment with the Company.Exhibit 10.1
​
SECOND AMENDMENT TO SURETY BOND BACKSTOP AGREEMENT
​
This SECOND AMENDMENT TO SURETY BOND BACKSTOP AGREEMENT (this “Amendment”) is entered into as of December 1, 2022 (the “Effective Date”), to the Surety Bond Backstop Agreement effective February 14, 2022, and as previously amended on July 18, 2022 (the “Agreement”), and is by and among CytoDyn Inc., a Delaware corporation (“CytoDyn”), David Fairbank Welch, both individually and in his capacity as trustee of the David F. and Heidi A. Welch Revocable Trust, Heidi A. Welch, both individually and in her capacity as trustee of the David F. and Heidi A. Welch Revocable Trust, LRFA, LLC, a Delaware limited liability company (“LRFA” and, together with David F. Welch, Heidi A. Welch, each an “Indemnitor” and collectively the “Indemnitors”), and 4-Good Ventures LLC (“4-Good”), a Delaware limited liability company (“4-Good”). CytoDyn, Indemnitors and 4-Good are collectively referred to herein as the “Parties” or each, individually, as a “Party”.
RECITALS
WHEREAS the Parties wish to amend the Agreement, as well as the Warrants (as defined in the Agreement).
NOW, THEREFORE, in consideration of the consideration set forth in this Amendment and certain other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree to amend the Agreement and the Warrants as specified below.
	1.
	Defined Terms. Terms used in this Amendment without definition shall have the meanings ascribed to them in the Agreement, as applicable.

	2.
	Extension of Term of Surety Bond Indemnity. Paragraph 6(b) of the Agreement is further amended and restated in its entirety as follows:

“(b) CytoDyn shall fully relieve the Indemnitors from the Surety Bond obligation not later than January 31, 2023, as follows:
		(i)
	on or before January 5, 2023, CytoDyn shall relieve Indemnitors of a minimum of $1,500,000 of cash collateral currently pledged by Indemnitors in support of the Surety Bond; and

		(ii)
	on or before January 31, 2023, CytoDyn shall relieve Indemnitors of the remainder of the cash collateral, $5,000,000, pledged by Indemnitors in support of the Surety Bond; provided, however, if on January 31, 2023, $1,000,000 or less of cash collateral remains outstanding, CytoDyn, at its sole discretion, can elect to have Indemnitors exchange the cash obligation for shares or warrants for the remaining balance.”

​

Page 1 – Amendment to Surety Bond Backstop Agreement – CytoDyn – Welch

	3.
	CytoDyn’s Paragraph 6(b)(ii) Option Regarding Indemnitors Purchase of Shares and/or Warrants. Provided that CytoDyn has complied in a timely fashion with its obligations under the amended Paragraph 6(b), and further provided that CytoDyn elects to exercise its option provided in the revised Paragraph 6(b)(ii) as outlined in Section 2 above, Indemnitors shall, on or before February 14, 2023, elect to:

		(i)
	purchase from CytoDyn shares with an aggregate fair market value on the date of such purchase of $1,000,000 (or less, as the amount may be determined);

		(ii)
	purchase warrants with an aggregate exercise price of $1,000,000 (or less, as the amount may be determined); and/or

		(iii)
	exercise Warrants with an aggregate exercise price of $1,000,000 (or less, as the amount may be determined).

The total of the $1,000,000 (or less, as the amount may be determined) shall be inclusive of an adjustment for an income tax true-up. The purchase price or aggregate exercise price, as the case may be, shall be paid in cash. Upon receipt of the consideration specified in this Section 3, CytoDyn shall obtain from Surety a full release of the Indemnitors’ obligations under the Surety Bond Indemnity.
For purposes of this Section 3, “fair market value” with respect to shares of CytoDyn shall mean the closing sale price of CytoDyn common stock as quoted on the OTCQB on the most recent date on which there was a sale of CytoDyn common stock prior to the date of purchase or exercise by Indemnitors.
	4.
	Amendments to Warrants. As consideration for the extension provided in Section 2 of this Amendment, CytoDyn hereby amends the pre-existing Warrants under the Agreement to provide as follows:

		(a)
	The Exercise Price of all 30 million shares covered by the Warrants shall be $0.10 per share.

	5.
	Award of Additional Warrants. As additional consideration for the extension provided in Section 2 of this Amendment, timely following the Effective Date, CytoDyn shall issue to Indemnitors:

		(i)
	a warrant for the purchase of seven million five hundred thousand (7,500,000) common shares of CytoDyn common stock at an exercise price of $0.10 per share (the “Extension Warrant”) with registration rights; and

​

2 – Second Amendment to Surety Bond Backstop Agreement – CytoDyn – Welch

		(ii)
	an additional warrant for the purchase of up to seven million five hundred thousand (7,500,000) common shares of CytoDyn common stock at an exercise price of $0.10 per share, with the exact amount to be determined (the “Optional Vesting Warrant”). Warrants issued under the Optional Vesting Warrant will be determined by how quickly CytoDyn is able to relieve Indemnitors of the Surety Bond obligation as provided in Paragraph 6(b)(ii). Warrants issued under the Optional Vesting Warrant will accrue based on the formula and hypothetical chart included in Schedule A hereto. The total warrants to be issued under the Optional Vesting Warrant will be calculated on or before February 14, 2023, and will include registration rights.

	6.
	Indemnity for Indemnitors. As additional consideration for the extension provided in Section 2 of this Amendment, and only in the event CytoDyn is unable to relieve Indemnitors of the Surety Bond obligation as contemplated by Section 2 above, CytoDyn agrees to indemnify Indemnitors for any fees incurred by Indemnitors as a result of legal action taken by the Surety against Indemnitors. For the purposes of this Section 6, legal action shall be limited to include legal proceedings relating to a collection effort initiated by the Surety, against the Indemnitors, as it relates to the Surety Bond obligation.

	7.
	Execution and Delivery of Additional Documents. Each of the Parties agrees to execute and deliver such other documents as one or more other Parties may request in order to carry out the transactions contemplated under the Agreement and this Amendment.

	8.
	General.

		(a)
	Captions. Any captions for the sections of this Amendment are for convenience only and do not control or affect the meaning or construction of any of the provisions of this Amendment.

		(b)
	Severability. If any term, condition, or provision of this Amendment, or any other document or instrument referred to in this Amendment, is held invalid for any reason, such offending term, condition, or provision shall be stricken therefrom, and the remainder of this Amendment shall not be affected thereby.

		(c)
	Negotiated Agreement. This Amendment is a negotiated agreement. In the event of any ambiguity in this Amendment, such ambiguity shall not be subject to a rule of contract interpretation that would cause the ambiguity to be construed against any of the parties to this Amendment.

		(d)
	Entire Agreement. Except as amended by this Second Amendment, all other provisions of the Agreement remain in full force and effect.

		(e)
	Applicable Law. This Amendment shall be governed by and construed under the laws of the State of Washington, without regard to principles of conflicts of law.

[Signature page follows]
​

3 – Second Amendment to Surety Bond Backstop Agreement – CytoDyn – Welch

IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the Effective Date.
​
	CytoDyn Inc., a Delaware corporation
	    
	​

	​
	​
	​
	​

	​
	​
	​
	​

	By:
	/s/ Antonio Migliarese
	​
	​

	Name:
	 Antonio Migliarese
	​
	David Fairbank Welch, both individually and in

	Title:
	CFO
	​
	his capacity as trustee of the David F. and

	​
	​
	​
	Heidi A. Welch Revocable Trust,

	4-Good Ventures, LLC, a Delaware
	​
	​

	limited liability company
	​
	​

	​
	​
	​
	​

	​
	​
	​
	​

	By:
	/s/ David F. Welch
	​
	Heidi A. Welch, both individually and in her

	Name:
	David F. Welch
	​
	capacity as trustee of the David F. and Heidi 

	Title:
	President
	​
	A. Welch Revocable Trust

	​
	​
	​
	​

	​
	​
	​
	​

	​
	​
	​
	LRFA LLC, a Delaware limited liability

	​
	​
	​
	company

	​
	​
	​
	​

	​
	​
	​
	By:
	/s/ David F. Welch

	​
	​
	​
	Name:
	David F. Welch

	​
	​
	​
	Title:
	President

​
​

4 – Second Amendment to Surety Bond Backstop Agreement – CytoDyn – Welch

SCHEDULE A
​
Consistent with Section 5(ii) of the Second Amendment to Surety Bond Backstop Agreement, warrants under the Optional Vesting Warrant may accrue up to the number of warrants indicated on the specified date if the full $6,500,000 Surety Bond obligation remains outstanding on the specified date (column A); however, this amount will be adjusted based on the percentage of the $6,500,000 Surety Bond obligation which remains outstanding as of the specified date (column B).
​
For the avoidance of doubt, the chart below does not represent payment commitments or obligations and is included strictly for illustrative purposes.
​
	​

	​

	​

	​

	​

	​

	​

	​

	​

	​

	​

	​

	​

	​

	​
	    
	(A)
	    
	​
	    
	​
	    
	    
	    
	(B)
	    
	(C) = A x B

	​
	​
	Potential 
Warrants to 
Be Issued
	​
	Beginning 
Balance
	​
	Payment
	​
	Ending 
Balance
	​
	% of Original 
Balance 
Outstanding
	​
	Warrant 
Issued

	12/6/2022
	​
	2,045,455
	​
	$
	6,500,000
	​
	—
	​
	6,500,000
	​
	100
	%  
	2,045,455

	12/13/2022
	​
	681,818
	​
	$
	6,500,000
	​
	—
	​
	6,500,000
	​
	100
	%  
	681,818

	12/20/2022
	​
	681,818
	​
	$
	6,500,000
	​
	(500,000)
	​
	6,000,000
	​
	92
	%  
	629,371

	12/27/2022
	​
	681,818
	​
	$
	6,000,000
	​
	(500,000)
	​
	5,500,000
	​
	85
	%  
	576,923

	1/3/2023
	​
	681,818
	​
	$
	5,500,000
	​
	(500,000)
	​
	5,000,000
	​
	77
	%  
	524,476

	1/10/2023
	​
	681,818
	​
	$
	5,000,000
	​
	(1,000,000)
	​
	4,000,000
	​
	62
	%  
	419,580

	1/17/2023
	​
	681,818
	​
	$
	4,000,000
	​
	(1,000,000)
	​
	3,000,000
	​
	46
	%  
	314,685

	1/24/2023
	​
	681,818
	​
	$
	3,000,000
	​
	(1,000,000)
	​
	2,000,000
	​
	31
	%  
	209,790

	1/31/2023
	​
	681,818
	​
	$
	2,000,000
	​
	(1,000,000)
	​
	1,000,000
	​
	15
	%  
	104,895

	Total
	​
	7,500,000
	​
	​
	​
	​
	(5,500,000)
	​
	​
	​
	​
	​
	5,506,993

​
(A) = # of potential warrant that can be issued if the balance is 100% ($6.5M) outstanding at specified date.
​
(B) = Current outstanding balance divided by original balance of $6.5M (% of current balance compared to originating balance) at specified date.
​
(C) = Actual total warrants issued calculated as the Potential Warrants to be Issued at specified multiplied by % of Originating Balance outstanding at specified date.

5 – Second Amendment to Surety Bond Backstop Agreement – CytoDyn – Welch

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]